Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Omontys (peginesatide) – for Treatment of Anaemia Associated with Chronic Kidney Disease

Drug (Brand / Generic)

Omontys / Peginesatide

Company

Affymax and Takeda Pharmaceutical Company

Therapy Class

Erythropoiesis-stimulating agent

Product Description

Synthetic peptide-based erythropoiesis-stimulating agent

Current Indication

Anaemia associated with chronic kidney disease

Market Sector

Anaemia

Development Status

Approved in the US, under review in Europe
Expand

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM

Go Top